secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gossamer Bio, Inc. (GOSS)
CIK:        0001728117
Form:       8-K
Filed at:   2022-05-10T23:59:59+00:00
Accession:  0001728117-22-000046
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gossamer Bio Q1 net loss $57.8M ($0.76/diluted); TORREY enrollment complete; cash $271.6M
--------------------------------------------------------------------------------

- Phase 2 TORREY study (seralutinib in PAH) completed enrollment; topline data expected Q4 2022.
- Cash, cash equivalents & marketable securities: $271.6M as of March 31, 2022; runway into first half 2024.
- Net loss of $57.8M ($0.76 per share) vs $57.6M ($0.78) in Q1 2021; R&D $42.3M, G&A $12.0M.
- GB5121 Phase 1b/2 STAR CNS study in PCNSL expected to initiate Q2 2022.
- GB7208 Phase 1 in neuroinflammatory diseases planned for H1 2023, pending TORREY results.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728117/000172811722000046/0001728117-22-000046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728117/000172811722000046/goss-20220510x8k.htm
  HTML page:      https://secwatch.observer/filing/0001728117-22-000046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer